Literature DB >> 31370979

Buprenorphine in the United States: Motives for abuse, misuse, and diversion.

Howard D Chilcoat1, Halle R Amick2, Molly R Sherwood3, Kelly E Dunn4.   

Abstract

Opioid use disorder (OUD) and its consequences are a major public health concern. The partial agonist buprenorphine is a safe and effective treatment for OUD, but concerns about abuse, misuse, and diversion of buprenorphine have been raised. This narrative review examined the rates and motives for use of illicit buprenorphine in the United States. Findings from the 17 included studies suggest the majority of study participants using illicit buprenorphine do so for reasons related to misuse (to manage opioid withdrawal symptoms or achieve or maintain abstinence from other opioids). A smaller percentage of study respondents reported using buprenorphine for reasons related to abuse (to get high). There appears to be a gap between need for buprenorphine and access to adequate treatment. Attenuation of policy-related barriers and adoption of appropriate buprenorphine use by the treatment community are critical tools in the continued effort to reduce the burdens associated with OUD.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Access to care; Buprenorphine; Health policy; Opioid abuse; Self-treatment

Year:  2019        PMID: 31370979     DOI: 10.1016/j.jsat.2019.07.005

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  19 in total

1.  Risk factors for heroin use following release from jail or prison in adults in a Central Appalachian state between 2012-2017.

Authors:  Kirsten Elin Smith; Adrian Archuleta; Michele Staton; Erin Winston
Journal:  Am J Drug Alcohol Abuse       Date:  2020-04-03       Impact factor: 3.829

2.  Medications for opioid use disorders: clinical and pharmacological considerations.

Authors:  Nora D Volkow; Carlos Blanco
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

3.  Toward evaluation of disseminated effects of medications for opioid use disorder within provider-based clusters using routinely-collected health data.

Authors:  Ashley Buchanan; Tianyu Sun; Jing Wu; Hilary Aroke; Jeffrey Bratberg; Josiah Rich; Stephen Kogut; Joseph Hogan
Journal:  Stat Med       Date:  2022-06-08       Impact factor: 2.497

4.  Acceptability and Feasibility of a Mobile Health Application for Video Directly Observed Therapy of Buprenorphine for Opioid Use Disorders in an Office-based Setting.

Authors:  Margo E Godersky; Jared W Klein; Joseph O Merrill; Kendra L Blalock; Andrew J Saxon; Jeffrey H Samet; Judith I Tsui
Journal:  J Addict Med       Date:  2020 Jul/Aug       Impact factor: 3.702

5.  Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.

Authors:  Kirsten E Smith; Martha D Tillson; Michele Staton; Erin M Winston
Journal:  Drug Alcohol Depend       Date:  2020-01-09       Impact factor: 4.492

6.  "The Doctor Says You Cannot Have [Buprenorphine]" Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine.

Authors:  Benjamin T Hayes; Andrea Jakubowski; Christine Fitzsimmons; Billy Garcia; Franklin Ramirez; Aaron D Fox
Journal:  Subst Use Misuse       Date:  2021-05-03       Impact factor: 2.164

7.  Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.

Authors:  Nicholas Lintzeris; Adrian J Dunlop; Paul S Haber; Dan I Lubman; Robert Graham; Sarah Hutchinson; Shalini Arunogiri; Victoria Hayes; Peter Hjelmström; Agneta Svedberg; Stefan Peterson; Fredrik Tiberg
Journal:  JAMA Netw Open       Date:  2021-05-03

8.  When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use.

Authors:  Kirsten E Smith; Jeffery M Rogers; Justin C Strickland; David H Epstein
Journal:  Am J Drug Alcohol Abuse       Date:  2021-04-28       Impact factor: 3.912

9.  Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder.

Authors:  Arthur Robin Williams; Christine M Mauro; Tianshu Feng; Amanda Wilson; Angelo Cruz; Mark Olfson; Stephen Crystal; Hillary Samples; Lisa Chiodo
Journal:  J Subst Abuse Treat       Date:  2022-03-21

10.  Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?

Authors:  Robert G Carlson; Raminta Daniulaityte; Sydney M Silverstein; Ramzi W Nahhas; Silvia S Martins
Journal:  Int J Drug Policy       Date:  2020-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.